Research-based insights to guide CDMO-CRO partnership decisions

In drug development, every delay has a price—lost time, lost opportunity and lost market share. Escalating costs, complex modalities, strict regulations and supply challenges make speed and precision more critical than ever. Yet many programs remain slowed by fragmented outsourcing models that create inefficiencies, communication gaps and costly handoffs.

Important new research from the Tufts Center for the Study of Drug Development points to a more effective path. Using a modeling approach that quantifies both the financial returns and risk-adjusted value of development decisions, the researchers found that integrating CDMO, CRO and clinical supply capabilities with one partner can shorten timelines, reduce costs, and strengthen control.

This webinar explores:

• The research methods and modeling techniques behind key findings from the study.
• Case-driven examples of how biotech and biopharma companies are applying these strategies to reach milestones faster and with greater strategic control.
• Benefits of Thermo Fisher Scientific’s Accelerator™ Drug Development 360^o CDMO and CRO framework.